Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological Parameters and fMRI in Seasonal Affective Disorder
DRKS00024756Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eicosapentaenoic acid and docosahexaenoic acid in major depressive disorder (MDD) (4 arms), sponsored by Medical University of Vienna. Started Mar 2021; status: completed.
02
Drugs
eicosapentaenoic aciddocosahexaenoic acid
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on DRKS00024756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00024756.